Ken Griffin's Citadel hedge fund places £305M short bet against GSK, with skepticism over long-term pipeline and recent stock ...

After years of limping along, the GSK share price has leapt 11% in one month. But one of America's richest investors is ...

The world’s most profitable hedge fund has started betting against shares in GSK (GSK), the first significant short on the FTSE 100 drugmaker’s stock for more than a decade, The Times’ Ben Martin ...

Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...

The FTSE 100 and European stocks were mixed at the open on Monday, as traders digest the potential of escalating tensions ...

Shares in TSMC (TSM, 2330.TW) rose more than 2% on Monday, after it was reported that the chipmaker was considering taking a ...

The FTSE 100 and European stocks were mixed at the open on Monday, as traders digest the potential of escalating tensions between European powers, Ukraine and Russia. London's pre ...

This summary covers the latest health news: Moderna's norovirus vaccine trial paused due to a rare neurological effect, Citadel's short position in GSK, bird flu response issues during Trump's term, ...

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in. The content of this article is provided for information ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

GSK licensed the drug from long-standing partner Ionis as part of a two-drug deal in 2019, paying $25 million upfront with milestone payments taking the value of the deal up to $262 million.